EGFR and non-small cell lung carcinoma: Despite a very high response rate (about 70%) to first-line treatment with the EGFR-TKIs (erlotinib, gefitinib or afatinib) in MUTEGFR NSCLC, tumors invariably progress after a median of 9–13 months from the beginning of treatment [1–3].